Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.22, pp.2117-2128, 2015. ,
DOI : 10.1056/NEJMoa1504720
trial, European Heart Journal, vol.37, issue.19, pp.1526-1534, 2016. ,
DOI : 10.1093/eurheartj/ehv728
Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes, Am J Med, vol.130, issue.6, pp.18-29, 2017. ,
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials, Diabetes and Vascular Disease Research, vol.369, issue.2, pp.90-100, 2015. ,
DOI : 10.2459/JCM.0000000000000039
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361459
Heart failure: SGLT2 inhibitors and heart failure ??? clinical implications, Nature Reviews Cardiology, vol.13, issue.4, pp.185-186, 2016. ,
DOI : 10.1016/j.ahj.2010.05.032
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.323-334, 2016. ,
DOI : 10.1056/NEJMoa1515920
EMPA-REG OUTCOME: The Nephrologist's Point of View, The American Journal of Medicine, vol.130, issue.6, pp.63-72, 2017. ,
DOI : 10.1016/j.amjmed.2017.04.007
SGLT2 Inhibitors and the Diabetic Kidney, Diabetes Care, vol.39, issue.Supplement 2, pp.165-171, 2016. ,
DOI : 10.2337/dcS15-3006
Sodium???glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy, Current Opinion in Nephrology and Hypertension, vol.24, issue.1, pp.96-103, 2015. ,
DOI : 10.1097/MNH.0000000000000084
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, vol.42, pp.1050-1065, 2003. ,
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney International, vol.80, issue.6, pp.572-586, 2011. ,
DOI : 10.1038/ki.2011.223
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, vol.375, pp.2073-2081, 2010. ,
Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999, Journal of the American Society of Nephrology, vol.16, issue.2, pp.489-495, 1998. ,
DOI : 10.1681/ASN.2004030203
Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes, Kidney International, vol.85, issue.5, pp.1192-1199, 2014. ,
DOI : 10.1038/ki.2013.396
Chronic Kidney Disease: Effects on the Cardiovascular System, Circulation, vol.116, issue.1, pp.85-97, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.106.678342
Haemostasis in chronic kidney disease, Nephrology Dialysis Transplantation, vol.29, issue.1, pp.29-40, 2014. ,
DOI : 10.1093/ndt/gft209
Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis, Diabetes & Metabolism, vol.42, issue.2, pp.71-76, 2016. ,
DOI : 10.1016/j.diabet.2015.12.005
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study, Diabetes Care, vol.39, issue.5, pp.717-725, 2016. ,
DOI : 10.2337/dc16-0041
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, New England Journal of Medicine, vol.369, issue.14, pp.1317-1326, 2013. ,
DOI : 10.1056/NEJMoa1307684
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes, New England Journal of Medicine, vol.369, issue.14, pp.1327-1335, 2013. ,
DOI : 10.1056/NEJMoa1305889
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.3, pp.232-242, 2015. ,
DOI : 10.1056/NEJMoa1501352
The EMPA-REG study: What has it told us? A diabetologist???s perspective, Journal of Diabetes and its Complications, vol.30, issue.1, pp.1-2, 2016. ,
DOI : 10.1016/j.jdiacomp.2015.10.013
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.372, issue.23, pp.2197-2206, 2015. ,
DOI : 10.1056/NEJMoa1414266
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes, New England Journal of Medicine, vol.359, issue.15, pp.1577-1589, 2008. ,
DOI : 10.1056/NEJMoa0806470
Revisiting the links between glycaemia, diabetes and cardiovascular disease, Diabetologia, vol.55, issue.Suppl 2, pp.686-695, 2013. ,
DOI : 10.1007/s00125-012-2817-5
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial, The Lancet, vol.382, issue.9896, pp.941-950, 2013. ,
DOI : 10.1016/S0140-6736(13)60683-2
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin, Diabetes, Obesity and Metabolism, vol.28, issue.Suppl. 1, pp.159-169, 2014. ,
DOI : 10.1111/dom.12189
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial, The Lancet Diabetes & Endocrinology, vol.2, issue.9, pp.691-700, 2014. ,
DOI : 10.1016/S2213-8587(14)70120-2
Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study, Diabetes Care, vol.31, issue.8, pp.1582-1584, 2008. ,
DOI : 10.2337/dc08-0025
Effects of Dapagliflozin on Cardiovascular Risk Factors, Postgraduate Medicine, vol.35, issue.6, pp.181-189, 2013. ,
DOI : 10.1056/NEJMoa1208500
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea, Diabetes Care, vol.36, issue.9, pp.2508-2515, 2013. ,
DOI : 10.2337/dc12-2491
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747923
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial, International Journal of Clinical Practice, vol.13, issue.Suppl. G, pp.1267-1282, 2013. ,
DOI : 10.1111/ijcp.12322
Uric Acid Levels, Kidney Function, and Cardiovascular Mortality in US Adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002, American Journal of Kidney Diseases, vol.64, issue.4, pp.550-557, 2014. ,
DOI : 10.1053/j.ajkd.2014.04.024
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177300
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin, Nutrition & Diabetes, vol.37, issue.11, p.143, 2014. ,
DOI : 10.2337/dc12-2491
Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae, Postgraduate Medicine, vol.358, issue.24, pp.90-97, 2012. ,
DOI : 10.1210/jc.2008-2534
Oxidative Stress and Diabetic Complications, Circulation Research, vol.107, issue.9, pp.1058-1070, 2010. ,
DOI : 10.1161/CIRCRESAHA.110.223545
O-GlcNAc and the cardiovascular system, Pharmacology & Therapeutics, vol.142, issue.1, pp.62-71, 2014. ,
DOI : 10.1016/j.pharmthera.2013.11.005
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943723
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease, Korean Diabetes Journal, vol.34, issue.4, pp.211-219, 2010. ,
DOI : 10.4093/kdj.2010.34.4.211
URL : http://doi.org/10.4093/kdj.2010.34.4.211
Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients, Circulation, vol.130, issue.7, pp.554-564, 2014. ,
DOI : 10.1161/CIRCULATIONAHA.113.008476
Empagliflozin improves beta-cell function measured with the hyperglycemic clamp in T2DM, Diabetes, vol.65, p.286, 2016. ,
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin, Metabolism, vol.65, issue.2, pp.114-123, 2016. ,
DOI : 10.1016/j.metabol.2015.10.010
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients, Journal of Clinical Investigation, vol.124, issue.2, pp.499-508, 2014. ,
DOI : 10.1172/JCI72227
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes, Diabetes Care, vol.39, issue.11, pp.2036-2041, 2016. ,
DOI : 10.2337/dc15-2688
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009, Diabetologia, vol.150, issue.Suppl 2, pp.1270-1287, 2009. ,
DOI : 10.1007/s00125-010-1684-1
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack, New England Journal of Medicine, vol.374, issue.14, pp.1321-1331, 2016. ,
DOI : 10.1056/NEJMoa1506930
The primary glucoselowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies, Diabetes Care, vol.39, pp.198-205, 2016. ,
Metformin Therapy in Diabetes: The Role of Cardioprotection, Current Atherosclerosis Reports, vol.26, issue.Suppl 2, p.314, 2013. ,
DOI : 10.1007/s11883-013-0314-z
Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases, European Heart Journal, vol.29, issue.2, pp.270-276, 2008. ,
DOI : 10.1093/eurheartj/ehm342
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes, European Heart Journal, vol.36, issue.27, pp.1718-1727, 2015. ,
DOI : 10.1093/eurheartj/ehv134
Diabetes Mellitus and Heart Failure, The American Journal of Medicine, vol.130, issue.6, pp.40-50, 2017. ,
DOI : 10.1016/j.amjmed.2017.04.010
The Failing Heart Relies on Ketone Bodies as a Fuel, Circulation, vol.133, pp.698-705, 2016. ,
DOI : 10.1161/CIRCULATIONAHA.115.017355
Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy, British Journal of Pharmacology, vol.101, issue.8, pp.2080-2090, 2014. ,
DOI : 10.1111/bph.12475
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976623
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis, Diabetes Care, vol.39, issue.7, pp.1115-1122, 2016. ,
DOI : 10.2337/dc16-0542
Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure, Circulation, vol.133, pp.706-716, 2016. ,
DOI : 10.1161/CIRCULATIONAHA.115.017545
EMPA-REG: Glucose excretion and lipid mobilization ??? not storage ??? saves lives, Journal of Diabetes and its Complications, vol.30, issue.4, p.753, 2016. ,
DOI : 10.1016/j.jdiacomp.2016.02.015
CV Protection in the EMPA-REG OUTCOME Trial: A ???Thrifty Substrate??? Hypothesis, Diabetes Care, vol.39, issue.7, pp.1108-1114, 2016. ,
DOI : 10.2337/dc16-0330
Failing Heart and Starving Brain, Circulation, vol.134, issue.4, pp.265-266, 2016. ,
DOI : 10.1161/CIRCULATIONAHA.116.022141
Empagliflozin???s Fuel Hypothesis: Not so Soon, Cell Metabolism, vol.24, issue.2, pp.200-202, 2016. ,
DOI : 10.1016/j.cmet.2016.07.018
??-hydroxybutyrate: Much more than a metabolite, Diabetes Research and Clinical Practice, vol.106, issue.2, pp.173-181, 2014. ,
DOI : 10.1016/j.diabres.2014.08.009
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414487
Ketone bodies as signaling metabolites, Trends in Endocrinology & Metabolism, vol.25, issue.1, pp.42-52, 2014. ,
DOI : 10.1016/j.tem.2013.09.002
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176946
Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation, Neuroscience, vol.145, issue.1, pp.256-264, 2007. ,
DOI : 10.1016/j.neuroscience.2006.11.065
Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions, Experimental Neurology, vol.211, issue.1, pp.85-96, 2008. ,
DOI : 10.1016/j.expneurol.2007.12.029
EMPA-REG ??? the ???diuretic hypothesis???, Journal of Diabetes and its Complications, vol.30, issue.1, pp.3-4, 2016. ,
DOI : 10.1016/j.jdiacomp.2015.10.012
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus, Cardiovascular Diabetology, vol.13, issue.1, p.28, 2014. ,
DOI : 10.1186/1475-2840-13-28
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus, European Heart Journal, vol.37, issue.42, pp.3192-3200, 2016. ,
DOI : 10.1093/eurheartj/ehw110
How is empagliflozin working in type 2 diabetes in EMPA-REG? Available at: http://www.medscape.com/viewarticle/ 865481, 2016. ,
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, vol.374, p.1092, 2016. ,
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. (Correspondence), N Engl J Med, vol.374, p.1094, 2016. ,
DOI : 10.1056/nejmoa1504720
Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, vol.362, pp.1575-1585, 2010. ,
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, The Lancet, vol.387, issue.10017, pp.435-443, 2016. ,
DOI : 10.1016/S0140-6736(15)00805-3
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics, Diabetes & Metabolism, vol.42, issue.4, pp.224-233, 2016. ,
DOI : 10.1016/j.diabet.2016.05.006
Blood Pressure Lowering in Type 2 Diabetes, JAMA, vol.313, issue.6, pp.603-615, 2015. ,
DOI : 10.1001/jama.2014.18574
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus, Circulation, vol.129, issue.5, pp.587-597, 2014. ,
DOI : 10.1161/CIRCULATIONAHA.113.005081
Sodium???glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney International, vol.89, issue.3, pp.524-526, 2016. ,
DOI : 10.1016/j.kint.2015.12.038
Empagliflozin, cardiovascular outcomes , and mortality in type 2 diabetes, N Engl J Med, vol.374, pp.1092-1093, 2016. ,
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?, Diabetologia, vol.166, issue.7, pp.1333-1339, 2016. ,
DOI : 10.1007/s00125-016-3956-x
URL : http://doi.org/10.1007/s00125-016-3956-x
Glucagon and heart in type 2 diabetes: new perspectives, Cardiovascular Diabetology, vol.4, issue.374, p.123, 2016. ,
DOI : 10.1161/CIR.0000000000000426
URL : http://doi.org/10.1186/s12933-016-0440-3
Minireview: Glucagon in Stress and Energy Homeostasis, Endocrinology, vol.153, issue.3, pp.1049-1054, 2012. ,
DOI : 10.1210/en.2011-1979
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281544
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion, Nature Medicine, vol.2, issue.5, pp.512-517, 2015. ,
DOI : 10.1038/nm.3828
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes, Kidney International, vol.86, issue.5, pp.1057-1058, 2014. ,
DOI : 10.1038/ki.2014.246
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes, Diabetes, Obesity and Metabolism, vol.375, issue.9, pp.853-862, 2013. ,
DOI : 10.1111/dom.12127
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension, Current Opinion in Nephrology and Hypertension, vol.25, issue.2, pp.81-86, 2016. ,
DOI : 10.1097/MNH.0000000000000199
Understanding EMPA-REG OUTCOME, The Lancet Diabetes & Endocrinology, vol.3, issue.12, pp.928-929, 2015. ,
DOI : 10.1016/S2213-8587(15)00424-6
Angiotensin-converting enzyme 2 and angiotensin 1???7: novel therapeutic targets, Nature Reviews Cardiology, vol.279, issue.7, pp.413-426, 2014. ,
DOI : 10.1038/nrcardio.2014.59
Sodium???Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport, Diabetes Care, vol.38, issue.12, pp.2344-2353, 2015. ,
DOI : 10.2337/dc15-0642
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys, Journal of Clinical Medicine Research, vol.8, issue.12, pp.844-847, 2016. ,
DOI : 10.14740/jocmr2760w
Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit, European Journal of Heart Failure, vol.28, issue.1, pp.22-29, 2008. ,
DOI : 10.1016/j.ejheart.2007.10.008
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes, Obesity and Metabolism, vol.53, issue.1, pp.83-90, 2012. ,
DOI : 10.1111/j.1463-1326.2011.01517.x
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome, New England Journal of Medicine, vol.373, issue.23, pp.2247-2257, 2015. ,
DOI : 10.1056/NEJMoa1509225
URL : http://www.zora.uzh.ch/119538/1/Lixisenatide%20in%20pts.pdf
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.311-322, 2016. ,
DOI : 10.1056/NEJMoa1603827